Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock

Abbott Laboratories (ABT) demonstrated robust Q2 2025 performance, with its Established Pharmaceuticals Division (EPD) sales growing 7.7% organically and Diabetes Care sales, driven by FreeStyle Libre, increasing 19.6% organically. Year-to-date, ABT shares have significantly outperformed the broader market and peers, gaining 16.8% despite a projected deceleration in emerging market growth and a substantial $700 million headwind from China's volume-based procurement policies impacting its Diagnostics segment. The company maintains a full-year 2025 organic sales growth guidance of 7.5-8.0% (ex-COVID testing), highlighting its operational resilience and strong market positioning amidst challenging global economic and geopolitical conditions, while trading at a discount to its industry.

Analysis

Abbott Laboratories (ABT) is demonstrating robust operational performance across key segments, despite a challenging macroeconomic and regulatory backdrop. The Established Pharmaceuticals Division (EPD) delivered strong Q2 2025 results with 7.7% organic growth, outpacing the projected deceleration in its core emerging markets. This growth is complemented by the high-momentum Diabetes Care business, where the FreeStyle Libre system drove a 19.6% organic increase in CGM sales to over $1.9 billion. The company's stock has significantly outperformed, gaining 16.8% year-to-date versus 7.7% for the S&P 500. However, this positive momentum is tempered by significant headwinds. Abbott faces a $700 million full-year sales headwind in its Diagnostics business from China's volume-based procurement (VBP) policies. Furthermore, while the company reaffirmed its full-year 2025 organic sales growth guidance of 7.5-8.0% (ex-COVID), consensus EPS estimates have seen downward revisions in the past 30 days, and adjusted SG&A expenses rose 5.3% year-over-year, signaling potential margin pressure. Despite these challenges, the stock trades at a forward five-year price-to-sales ratio of 4.92X, a discount to the industry average of 5.38X.

Key Decisions for Investors

• Given the strong organic growth in key divisions and a valuation discount relative to the industry, investors may view the stock as a compelling opportunity, particularly on any price weakness caused by broader market concerns.
• It is critical to monitor the realized impact of China's VBP policy on the Diagnostics segment and watch for any further downward revisions to consensus earnings estimates, as these are the primary risks to the current investment thesis.
• Investors should weigh the company's confirmed high single-digit organic growth guidance against the rising operating expenses and geopolitical headwinds when assessing the sustainability of its recent stock outperformance.